IOL Chemicals and Pharmaceuticals growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+11.5%−2.5%−3.8%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+33.0%−12.3%+2.2%
+44.8%−22.3%−6.6%
+36.2%−24.8%−3.4%
+36.3%−85.0%−3.4%
+8.6%+6.1%+11.0%
+6.6%+4.7%+6.9%
+20.0%−38.4%+137.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

IOLCP₹184.93

IOL Chemicals and Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersMOREPENLABFDCINNOVACAPORCHPHARMASENORESSANOFIGUJTHEMRPGLIFEMcap ₹5,429 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-3.8-2.5+11.5—
EBITDA Growth—+2.2-12.3+33.0—
EBIT Growth—-6.6-22.3+44.8—
Net Income Growth—-3.4-24.8+36.2—
EPS Growth—-3.4-85.0+36.3—
Total Assets Growth—+11.0+6.1+8.6—
Total Equity Growth—+6.9+4.7+6.6—
Cash from Operations Growth—+137.2-38.4+20.0—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.